NEW YORK (GenomeWeb) – BioGx announced today that Switzerland's AxonLab will distribute assay products from BioGx's European-based subsidiary in multiple European countries.
As part of the multi-year collaboration, AxonLab will work with a Netherlands-based subsidiary of Birmingham, Alabama-based BioGx to distribute its products to the majority of Central Europe, including Austria, Belgium, the Czech Republic, Germany, Slovenia, Switzerland, and Croatia. Distribution will include all of BioGx's CE-IVD product line, as well as laboratory-use-only products.
Markus Koller, head of molecular division of AxonLab, noted that the ready-to-use format of BioGX's lyophilized assays allows for accurate and rapid detection of infectious microorganisms.
"[The partnership] allows us to complete our portfolio with an expanding menu of high-quality, cost-effective, CE-IVD-marked real-time PCR assays for automated qPCR platforms," Koller said in a statement.
According to Ken Gordon, BioGx VP of sales and marketing, the partnership will improve delivery timetables and allow for more competitive pricing for European customers, in addition to streamlining customer support.
In April 2017, BioGx received CE-IVD marking for four real-time PCR-based tests for infectious diseases. In October 2016, the firm received CE marking for qPCR tests for Influenza A, Influenza B, and respiratory syncytial virus tests.